Clear All
12250 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
53808-0411-01 53808-0411 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jul 1, 2009 In Use
72606-0555-01 72606-0555 Capecitabine Capecitabine 500mg 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov 6, 2019 In Use
42291-0166-60 42291-0166 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral May 11, 2018 Nov 19, 2018 In Use
59923-0721-60 59923-0721 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Mar 1, 2020 In Use
72485-0204-60 72485-0204 Capecitabine Capecitabine 150mg 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Mar 1, 2019 In Use
72205-0006-60 72205-0006 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jul 21, 2018 In Use
54868-5260-05 54868-5260 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jun 28, 2005 In Use
55111-0496-60 55111-0496 capecitabine capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec 10, 2020 In Use
73591-5886-01 73591-5886 CALCIUM FOLINATE LEDERLE LEUCOVORIN 5.0 mg/1 Ancillary Therapy Chemoprotective Antidote Oral Nov 26, 2025 In Use
00069-5886-99 00069-5886 Calcium folinate LEDERLE LEUCOVORIN 5.0 mg/1 Ancillary Therapy Chemoprotective Antidote Oral Dec 18, 2025 Mar 31, 2027 In Use
73591-5886-02 73591-5886 CALCIUM FOLINATE LEDERLE LEUCOVORIN 5.0 mg/1 Ancillary Therapy Chemoprotective Antidote Oral Nov 26, 2025 In Use
00069-5886-24 00069-5886 Calcium folinate LEDERLE LEUCOVORIN 5.0 mg/1 Ancillary Therapy Chemoprotective Antidote Oral Dec 18, 2025 Mar 31, 2027 In Use
72694-0515-01 72694-0515 Calaspargase Pegol Asparlas 750.0 U/mL Chemotherapy Miscellaneous Agent Enzyme Intravenous Sep 27, 2019 In Use
42388-0023-37 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Oct 3, 2018 In Use
42388-0023-46 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan 9, 2023 In Use
42388-0024-26 42388-0024 Cabozantinib CABOMETYX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Apr 25, 2016 In Use
42388-0024-46 42388-0024 Cabozantinib CABOMETYX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan 9, 2023 In Use
42388-0024-37 42388-0024 Cabozantinib CABOMETYX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Feb 27, 2019 In Use
42388-0025-46 42388-0025 Cabozantinib CABOMETYX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan 9, 2023 In Use
42388-0023-26 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Apr 25, 2016 In Use
42388-0023-57 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan 9, 2023 In Use
42388-0023-36 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov 16, 2017 In Use
42388-0025-37 42388-0025 Cabozantinib CABOMETYX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Feb 27, 2019 In Use
42388-0013-14 42388-0013 Cabozantinib COMETRIQ 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov 29, 2012 In Use
42388-0024-57 42388-0024 Cabozantinib CABOMETYX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan 9, 2023 In Use

Found 12250 results — Export these results